Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Immunization & Vaccines

Reports

Displaying 1 - 10 of 16. 10 per page. Page 1.

Advanced Search
ASPE Issue Brief

Reductions in Deaths and Hospitalizations Associated with COVID-19 Vaccinations Among Medicare Beneficiaries: Full Year 2021 Estimates

October 7, 2022
This study updates ASPE’s previous analysis of the associations between COVID-19 hospitalizations and deaths among Medicare beneficiaries and COVID-19 vaccination rates, with full year data through the end of 2021.
Report

Understanding Coverage Considerations for COVID-19 Vaccines and Treatments

August 31, 2022
COVID-19 vaccines and treatments have been an important tool in the prevention of COVID-19, including preventing hospitalizations and deaths.
ASPE Data Point

Hospitalization Cost Savings Associated with COVID-19 Vaccinations Among Medicare Beneficiaries in Early 2021

May 4, 2022
Using Medicare FFS claims data and county-level vaccination rates, we estimate savings of about $2.6 billion from reduced Medicare hospitalizations associated with COVID-19 vaccinations in early 2021.
ASPE Issue Brief

Trends in COVID-19 Vaccination Intentions

April 5, 2022
We document a number of key facts related to trends in COVID-19 vaccination intentions of unvaccinated adults in the United States from April 2021 to January 2022 using the Household Pulse Survey. First, among unvaccinated adults both those who were willing to vaccinate and those who were previously unwilling to vaccinate eventually vaccinated in large numbers.
ASPE Issue Brief

Demographic Characteristics of Adults Receiving COVID-19 Booster Vaccinations

March 18, 2022
This ASPE issue brief examines demographic characteristics of adults receiving booster doses of COVID-19 vaccines using data from the U.S. Census Bureau's Household Pulse Survey. As of March 9, 2022, 47.5 percent of the fully vaccinated adult population has received a booster.
ASPE Issue Brief

Parents’ Intentions to Vaccinate Children for COVID-19 by Child Age: Sociodemographic Factors and Reasons for Hesitancy

February 2, 2022
This ASPE issue brief examines hesitancy among parents to vaccinate children ages 5-11 and 12-17 using data from the U.S. Census Bureau's Household Pulse Survey. Overall, a larger percent of parents with children aged 5-11 are hesitant to vaccinate their children (34 percent) than parents of children aged 12-17 (21 percent).
Research Brief

COVID-19 Vaccination Associated with Reductions in COVID-19 Mortality and Morbidity in the United States, and an Approach to Valuing these Benefits

December 15, 2021
This ASPE Research Report models the estimated reductions in COVID-19 cases, hospitalizations, and deaths associated with COVID-19 vaccination from December 2020 through July 2021. To download the Research Report, please download the PDF to the right under “Files”. To explore our dashboard that presents the Report’s results, please see below.
Research Brief

Associations Between County-level Vaccination Rates and COVID-19 Outcomes Among Medicare Beneficiaries in Early 2021

October 5, 2021
The purpose of this study is to identify associations between COVID-19 infections, hospitalizations, and deaths among Medicare fee-for-service (FFS) beneficiaries and the proportion of the population fully vaccinated at the county-level between January and May 2021.
ASPE Issue Brief

Parents' Intentions to Vaccinate Children Ages 12-17 for COVID-19: Demographic Factors, Geographic Patterns, and Reasons for Hesitancy

September 30, 2021
As of September 13, 2021, three vaccines to prevent infection with SARS-CoV-2, the virus that causes COVID-19, are available in the United States. The Pfizer vaccine was granted full approval for use in individuals over the age of 16 by the U.S.